ARCHIVES

Centers Of Excellence In Interventions Aimed at molecular Targets; Approved On 19-6 Vote

This article is from The Cancer Letter archive.

Vol. 25 No. 26 | July 2, 1999

Download PDF Visit The Full Archive

Related Articles

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

July 26, 2002

In Brief: Immunologists Boycott USSR Trip; Centers Program Staff Reorganized, Trimmed Down

June 2, 1978

NCI STRAP Grants Aim To Move Research Quickly To Clinical Trials

October 1, 2010

ASCO Recommends Discussing Pharmacological Prevention

July 26, 2013

ODAC Recommendation for Pertuzumab Signals FDA’s Resolve In Granting Accelerated Approvals

September 20, 2013

NCI Bypass Budget Seeks $3.64 Billion

January 20, 1995